The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide

Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schmitt, Stefan (VerfasserIn) , Ho, Anthony Dick (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 19 2010
In: Onkologie
Year: 2010, Jahrgang: 33, Heft: 4, Pages: 183-186
ISSN:1423-0240
DOI:10.1159/000286447
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1159/000286447
Verlag, lizenzpflichtig, Volltext: https://karger.com/onk/article-abstract/33/4/183/247593/The-Oral-Histone-Deacetylase-Inhibitor-LBH589-Is-a
Volltext
Verfasserangaben:Stefan Schmitt, Anthony D. Ho, Hartmut Goldschmidt
Beschreibung
Zusammenfassung:Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impairment. LBH589 is a histone deacetylase inhibitor with an epigenetic mechanism of action and the potential for treatment in myeloma. We report here about the successful treatment of a 44-year-old woman suffering from progressive myeloma with LBH589 after five different chemotherapies. During the 9 years after first diagnosis of myeloma in April 2000, our patient twice underwent an autologous stem cell transplantation and was also treated with the new substances bortezomib, thalidomide and lenalidomide.
Beschreibung:Gesehen am 14.06.2023
Beschreibung:Online Resource
ISSN:1423-0240
DOI:10.1159/000286447